EMAGIN CORP Form 10-Q August 06, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 10-Q

(Mark One)

R QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

Of

 \pounds TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-15751

eMAGIN CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 56-1764501 (I.R.S. Employer Identification No.)

3006 Northup Way, Suite 103, Bellevue, Washington 98004 (Address of principal executive offices)

(425) 284-5200 (Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock, \$.001 Par Value Per Share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes R No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ($\S232.405$ of this chapter) during the preceding 12 months). Yes R No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer £ Accelerated filer £

Non-accelerated filer £

Smaller reporting company R

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act) Yes \pounds No R

The number of shares of common stock outstanding as of July 31, 2013 was 23,864,592.

eMagin Corporation

Form 10-Q For the Quarter ended June 30, 2013

Table of Contents

PART I FINANCIAL INFORMATION	ON .	Page
<u>Item 1</u>	Condensed Consolidated Financial Statements	
	Condensed Consolidated Balance Sheets as of June 30, 2013 (unaudited) and December 31, 2012	<u>3</u>
	Condensed Consolidated Statements of Operations for the Three and Six Months ended June 30, 2013 and 2012 (unaudited)	<u>4</u>
	Condensed Consolidated Statements of Cash Flows for the Three and Six Months ended June 30, 2013 and 2012 (unaudited)	<u>5</u>
	Notes to Condensed Consolidated Financial Statements (unaudited)	<u>6</u>
<u>Item 2</u>	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>13</u>
Item 3	Quantitative and Qualitative Disclosures About Market Risk	<u>17</u>
<u>Item 4</u>	Controls and Procedures	<u>17</u>
PART II OTHER INFORMATION <u>Item 1</u>	Legal Proceedings	<u>18</u>
Item 1A	Risk Factors	<u>18</u>
<u>Item 2</u>	Unregistered Sales of Equity Securities and Use of Proceeds	<u>18</u>
Item 3	Defaults Upon Senior Securities	<u>18</u>
<u>Item 4</u>	Mine Safety Disclosures	<u>18</u>
<u>Item 5</u>	Other Information	<u>18</u>
<u>Item 6</u>	<u>Exhibits</u>	<u>18</u>
<u>SIGNATURES</u>	1	9

ITEM 1. Condensed Consolidated Financial Statements

eMAGIN CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

	June 30, 2013 (unaudited)	December 31, 2012
ASSETS		
Current assets:		
Cash and cash equivalents	\$4,605	\$4,385
Investments	8,753	8,520
Accounts receivable, net	4,863	5,154
Inventories, net	3,562	3,223
Prepaid expenses and other current assets	740	653
Total current assets	22,523	21,935
Long-term investments	_	500
Equipment, furniture and leasehold improvements, net	8,222	8,099
Other assets	122	124
Deferred tax asset	8,881	8,881
Total assets	\$39,748	\$39,539
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$908	\$955
Accrued expenses	2,308	2,548
Other current liabilities	374	409
Total current liabilities	3,590	3,912
Commitments and contingencies (Note 8)		
Shareholders' equity:		
Preferred stock, \$.001 par value: authorized 10,000,000 shares:		
Series B Convertible Preferred stock, (liquidation preference of \$5,659,000) stated value		
\$1,000 per share, \$.001 par value: 10,000 shares designated and 5,659 issued and		
outstanding as of June 30, 2013 and December 31, 2012		
Common stock, \$.001 par value: authorized 200,000,000 shares, issued and outstanding,		
23,838,156 shares as of June 30, 2013 and 23,674,541 as of December 31, 2012	24	24
Additional paid-in capital	224,910	223,575
Accumulated deficit		
1 localitatatea activit	(188,313) (187,309)
Treasury stock, 150,000 shares as of June 30, 2013 and December 31, 2012		(187,509) (463)

See notes to Condensed Consolidated Financial Statements.

eMAGIN CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data) (unaudited)

		Three Months Ended June 30,		onths Ended ine 30,
Revenue:	2013	2012	2013	2012
Product	\$6,773	\$7,124	\$14,901	\$12,954
Contract	255	1,463	630	1,770
Total revenue, net	7,028	8,587	15,531	14,724
Cost of goods sold:				
Product	4,437	3,480	8,974	6,782
Contract	200	594	416	748
Total cost of goods sold	4,637	4,074	9,390	7,530
Gross profit	2,391	4,513	6,141	7,194
Operating expenses:				
Research and development	1,454	1,258	2,643	2,398
Selling, general and administrative	2,077	2,344	4,317	4,607
Total operating expenses	3,531	3,602	6,960	7,005
(Loss) income from operations	(1,140) 911	(819) 189
Other income (expense):				
Interest expense, net	(11) (5) (21) (8)
Other income, net	23	12	36	18
Total other income (expense), net	12	7	15	10
(Loss) income before (benefit from) provision for income				
taxes	(1,128) 918	(804) 199
(Benefit from) provision for income taxes	(120) 341	_	74
Net (loss) income	\$(1,008) \$577	\$(804) \$125
Less net income allocated to participating securities		140		30
Net (loss) income allocated to common shares	\$(1,008) \$437	\$(804) \$95
(Loss) income per share, basic	\$(0.04) \$0.02	\$(0.03) \$0.00
(Loss) income per share, diluted	\$(0.04) \$0.02	\$(0.03) \$0.00
Weighted average number of shares outstanding:				

Basic	23,586,413	23,469,777	23,556,743	23,488,475
Diluted	23,586,413	25,167,605	23,556,743	25,344,779

See notes to Condensed Consolidated Financial Statements.

eMAGIN CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)

2013 (cunautive) Cash flows from operating activities: Net (loss) income \$ (804) \$ 125 Adjustments to reconcile net (loss) income to net cash provided by operating activities: 425 111 Adjustments to reconcile net (loss) income to net cash provided by operating activities: 425 111 Amortization of bond premium 17 — Inventory reserve 16 — Stock-based compensation 1,078 1,400 Gain on sale of asset 69 — Changes in operating assets and liabilities: 292 (1,258) Accounts receivable 292 (1,258) Inventories (355) 396 Prepaid expenses and other current assets 48 4 Accounts payable, accrued expenses, and other current liabilities 320 387 Perpaid expenses and other current liabilities 320 387 Cash flows from investing activities 252 422 Purchase of equipment (552) 1,042 Proceeds from sale of asset 15 —		June 30,			
Cash flows from operating activities: Net flows from operating activities: Net floss) income \$ (804) \$ 125 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Secondary and amortization 425 111 Amortization of bond premium 17 — Inventory reserve 16 — Stock-based compensation 1,078 1,400 Gain on sale of asset 292 (1,258) Changes in operating assets and liabilities: 292 (1,258) Inventories 292 (1,258) Inventories 355 396 Prepaid expenses and other current assets 48 4 Accounts payable, accrued expenses, and other current liabilities 320 428 Net cash provided by operating activities 250 387 Cash flows from investing activities 250 387 Unchase of equipment (552) (1,042) Proceeds from sale of asset 15 — Maturities of investments 7,250 4,000 Purchase of investments <td></td> <td></td> <td></td> <td>50,</td> <td></td>				50,	
Cash flows from operating activities: \$ (804) \$ 125 Adjustments to reconcile net (loss) income to net cash provided by operating activities: 3425 111 Depreciation and amortization 425 111 Amortization of bond premium 17 — Inventory reserve 16 — Stock-based compensation 1,078 1,400 Gain on sale of asset (9) — Changes in operating assets and liabilities: 292 (1,258) Inventories (355) 396 Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities: 250 387 Purchase of equipment (552) (1,042) Proceeds from sale of asset 15 — Maturities of investments 7,250 4,000 Purchase of investments (7,000) (6,549) Net cash used in investing activities 257 <					
Net (loss) income (804) 125 Adjustments to reconcile net (loss) income to net cash provided by operating activities: 111 Depreciation and amortization 425 111 Amortization of bond premium 17 — Inventory reserve 16 — Stock-based compensation 1,078 1,400 Gain on sale of asset (9) — Changes in operating assets and liabilities: 292 (1,258) Accounts receivable 292 (1,258) Inventories (355) 396 Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities: 250 387 Purchase of equipment (552) (1,042) Proceeds from sale of asset 15 — Maturities of investments 7,250 4,000 Purchase of investments (7,000) (6,549) Net cash used in	Cash flows from operating activities:		(unuu	arte	4)
Adjustments to reconcile net (loss) income to net cash provided by operating activities: 425 111 Depreciation and amortization 17 — Inventory reserve 16 — Stock-based compensation 1,078 1,400 Gain on sale of asset (9) — Changes in operating assets and liabilities: *** *** Accounts receivable 292 (1,258) Inventories (355) 396 Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities: *** *** Purchase of equipment (552) (1,042) Proceeds from sale of asset 15 — Maturities of investments 7,250 4,000 Purchase of investments (7,000) (6,549) Net cash used in investing activities (287) (3,591) Cash flows from financing activities: *** Proceeds from exercise of stock options 257 42	* *	\$	(804)	\$	125
Depreciation and amortization 425 111 Amortization of bond premium 17 — Inventory reserve 16 — Stock-based compensation 1,078 1,400 Gain on sale of asset (9) — Changes in operating assets and liabilities: *** *** Accounts receivable 292 (1,258) Inventories (355) 396 Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities 250 387 Cash flows from investing activities 552 (1,042) Proceeds from sale of asset 15 — Maturities of investments 7,250 4,000 Purchase of investments (7,000) (6,549) Net cash used in investing activities 287 42 Purchase of treasury stock 257 42 Purchase of treasury stock		4	(00.)	Ψ	120
Amortization of bond premium 17 — Inventory reserve 16 — Stock-based compensation 1,078 1,400 Gain on sale of asset (9) — Changes in operating assets and liabilities: 292 (1,258) Accounts receivable 292 (1,258) Inventories (355) 396 Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities 250 387 Urchase of equipment (552) (1,042) Proceeds from sale of asset 15 — Maturities of investments 7,250 4,000 Purchase of investments (7,000) (6,549) Net cash used in investing activities 287 42 Purchase of treasury stock — (368) Net cash provided by (used in) financing activities 257 42 Purchase of treasury s			425		111
Inventory reserve 16 — Stock-based compensation 1,078 1,400 Gain on sale of asset (9) — Changes in operating assets and liabilities: **** Accounts receivable 292 (1,258) Inventories (355) 396 Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities: *** 15 — Purchase of equipment (552) (1,042) *** Proceeds from sale of asset 15 — *** Auturities of investments 7,250 4,000 Purchase of investments (7,000) (6,549) Net cash used in investing activities 287 (3,591) Cash flows from financing activities 257 42 Purchase of treasury stock — (368) Net cash provided by (used in) financing activities 257 (326) <td>•</td> <td></td> <td>_</td> <td></td> <td>_</td>	•		_		_
Stock-based compensation 1,078 1,400 Gain on sale of asset (9) — Changes in operating assets and liabilities:	•				_
Gain on sale of asset (9) — Changes in operating assets and liabilities: 292 (1,258) Accounts receivable 292 (1,258) Inventories (355) 396 Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities:	•				1,400
Changes in operating assets and liabilities: 292 (1,258) Accounts receivable 295 (1,258) Inventories (355) 396 Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities: *** *** Purchase of equipment (552) (1,042) Proceeds from sale of asset 15 — Maturities of investments 7,250 4,000 Purchase of investments (7,000) (6,549) Net cash used in investing activities (287) (3,591) Cash flows from financing activities: *** *** Proceeds from exercise of stock options 257 42 Purchase of treasury stock — (368) Net cash provided by (used in) financing activities 257 (326) Net increase (decrease) in cash and cash equivalents 220 (3,530) Cash and cash equivalents, beginning of period 4,385 7,571	•				_
Accounts receivable 292 (1,258) Inventories (355) 396 Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities: *** *** Purchase of equipment (552) (1,042) Proceeds from sale of asset 15 *** Maturities of investments 7,250 4,000 Purchase of investments (7,000) (6,549) Net cash used in investing activities (287) (3,591) Cash flows from financing activities: *** 42 Purchase of treasury stock ** (368) Net cash provided by (used in) financing activities 257 (326) Net increase (decrease) in cash and cash equivalents 220 (3,530) Cash and cash equivalents, beginning of period 4,385 7,571	Changes in operating assets and liabilities:				
Prepaid expenses and other current assets (88) 41 Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities: *** *** Purchase of equipment (552) (1,042) Proceeds from sale of asset 15 — Maturities of investments 7,250 4,000 Purchase of investments (7,000) (6,549) Net cash used in investing activities (287) (3,591) Cash flows from financing activities: *** — (368) Purchase of treasury stock — (368) Net cash provided by (used in) financing activities 257 (326) Net increase (decrease) in cash and cash equivalents 220 (3,530) Cash and cash equivalents, beginning of period 4,385 7,571			292		(1,258)
Accounts payable, accrued expenses, and other current liabilities (322) (428) Net cash provided by operating activities 250 387 Cash flows from investing activities:	Inventories		(355)		396
Net cash provided by operating activities250387Cash flows from investing activities:387Purchase of equipment(552)(1,042)Proceeds from sale of asset15—Maturities of investments7,2504,000Purchase of investments(7,000)(6,549)Net cash used in investing activities(287)(3,591)Cash flows from financing activities:Proceeds from exercise of stock options25742Purchase of treasury stock—(368)Net cash provided by (used in) financing activities257(326)Net increase (decrease) in cash and cash equivalents220(3,530)Cash and cash equivalents, beginning of period4,3857,571	Prepaid expenses and other current assets		(88)		41
Cash flows from investing activities:(552)(1,042)Purchase of equipment(552)(1,042)Proceeds from sale of asset15—Maturities of investments7,2504,000Purchase of investments(7,000)(6,549)Net cash used in investing activities(287)(3,591)Cash flows from financing activities:Proceeds from exercise of stock options25742Purchase of treasury stock—(368)Net cash provided by (used in) financing activities257(326)Net increase (decrease) in cash and cash equivalents220(3,530)Cash and cash equivalents, beginning of period4,3857,571	Accounts payable, accrued expenses, and other current liabilities		(322)		(428)
Purchase of equipment(552)(1,042)Proceeds from sale of asset15—Maturities of investments7,2504,000Purchase of investments(7,000)(6,549)Net cash used in investing activities(287)(3,591)Cash flows from financing activities:Proceeds from exercise of stock options25742Purchase of treasury stock—(368)Net cash provided by (used in) financing activities257(326)Net increase (decrease) in cash and cash equivalents220(3,530)Cash and cash equivalents, beginning of period4,3857,571	Net cash provided by operating activities		250		387
Proceeds from sale of asset Maturities of investments 7,250 4,000 Purchase of investments (7,000) Net cash used in investing activities Cash flows from financing activities: Proceeds from exercise of stock options Purchase of treasury stock Purchase of treasury stock Net cash provided by (used in) financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of period 15 (3,549) (3,591) (368) (Cash flows from investing activities:				
Maturities of investments7,2504,000Purchase of investments(7,000)(6,549)Net cash used in investing activities(287)(3,591)Cash flows from financing activities:Proceeds from exercise of stock options25742Purchase of treasury stock—(368)Net cash provided by (used in) financing activities257(326)Net increase (decrease) in cash and cash equivalents220(3,530)Cash and cash equivalents, beginning of period4,3857,571	Purchase of equipment		(552)		(1,042)
Purchase of investments(7,000)(6,549)Net cash used in investing activities(287)(3,591)Cash flows from financing activities:Proceeds from exercise of stock options25742Purchase of treasury stock—(368)Net cash provided by (used in) financing activities257(326)Net increase (decrease) in cash and cash equivalents220(3,530)Cash and cash equivalents, beginning of period4,3857,571	Proceeds from sale of asset		15		_
Net cash used in investing activities (287) (3,591) Cash flows from financing activities: Proceeds from exercise of stock options 257 42 Purchase of treasury stock — (368) Net cash provided by (used in) financing activities 257 (326) Net increase (decrease) in cash and cash equivalents 220 (3,530) Cash and cash equivalents, beginning of period 4,385 7,571	Maturities of investments		7,250		4,000
Cash flows from financing activities:25742Proceeds from exercise of stock options25742Purchase of treasury stock—(368)Net cash provided by (used in) financing activities257(326)Net increase (decrease) in cash and cash equivalents220(3,530)Cash and cash equivalents, beginning of period4,3857,571	Purchase of investments		(7,000)		(6,549)
Proceeds from exercise of stock options25742Purchase of treasury stock—(368)Net cash provided by (used in) financing activities257(326)Net increase (decrease) in cash and cash equivalents220(3,530)Cash and cash equivalents, beginning of period4,3857,571	Net cash used in investing activities		(287)		(3,591)
Purchase of treasury stock— (368)Net cash provided by (used in) financing activities257 (326)Net increase (decrease) in cash and cash equivalents220 (3,530)Cash and cash equivalents, beginning of period4,385 7,571	Cash flows from financing activities:				
Net cash provided by (used in) financing activities257(326)Net increase (decrease) in cash and cash equivalents220(3,530)Cash and cash equivalents, beginning of period4,3857,571	Proceeds from exercise of stock options		257		42
Net increase (decrease) in cash and cash equivalents220(3,530)Cash and cash equivalents, beginning of period4,3857,571	•		_	_	(368)
Cash and cash equivalents, beginning of period 4,385 7,571	Net cash provided by (used in) financing activities		257		(326)
Cash and cash equivalents, end of period \$ 4,605 \$ 4,041	Cash and cash equivalents, beginning of period		4,385		7,571
	Cash and cash equivalents, end of period	\$	4,605	\$	4,041
Cash paid for interest, net of amount capitalized of \$13 thousand in 2012 \$ 3 \$ —	•				_
Cash paid for taxes \$ 20 \$ —	Cash paid for taxes	\$	20	\$	

See notes to Condensed Consolidated Financial Statements.

Six Months Ended

Table of Contents

eMAGIN CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

Note 1: Summary of Significant Accounting Policies

The Business

eMagin Corporation (the "Company") designs, develops, manufactures, and markets OLED (organic light emitting diode) on silicon microdisplays and virtual imaging products which utilize OLED microdisplays. The Company's products are sold mainly in North America, Asia, and Europe.

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements of eMagin Corporation and its subsidiary reflect all adjustments, including normal recurring accruals, necessary for a fair presentation. All significant intercompany balances and transactions have been eliminated in consolidation. Certain information and footnote disclosure normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the Securities and Exchange Commission. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. The results of operations for the period ended June 30, 2013 are not necessarily indicative of the results to be expected for the full year. The consolidated condensed financial statements of December 31, 2012 are derived from audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.

In accordance with accounting principles generally accepted in the United States of America, management utilizes certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments related to, among others, allowance for doubtful accounts, warranty reserves, inventory reserves, stock-based compensation expense, deferred tax asset valuation allowances, litigation and other loss contingencies. Management bases its estimates and judgments on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

Revenue and Cost Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, selling price is fixed or determinable and collection is reasonably assured. Product revenue is generally recognized when products are shipped to customers. The Company defers revenue recognition on products sold directly to the consumer with a maximum thirty day right of return. Revenue is recognized upon the expiration of the right of return.

The Company also earns revenues from certain research and development ("R&D") activities (contract revenues) under both firm fixed-price contracts and cost-type contracts. Revenues relating to firm fixed-price contracts and cost-type contracts are generally recognized on the percentage-of-completion method of accounting as costs are incurred (cost-to-cost basis). Progress is generally based on a cost-to-cost approach however an alternative method may be used such as physical progress, labor hours or others depending on the type of contract. Physical progress is

determined as a combination of input and output measures as deemed appropriate by the circumstances. Contract costs include all direct material and labor costs and an allocation of allowable indirect costs as defined by each contract, as periodically adjusted to reflect revised agreed upon rates. These rates are subject to audit by the other party.

Investments

Investments consist of debt securities including corporate obligations and FDIC-insured certificates of deposit with maturities up to twelve months. The Company classifies these securities as held-to-maturity since it has the positive intent and ability to hold them until maturity. These securities are carried at amortized cost.

The held-to-maturity investments consist of the following as of June 30, 2013 and December 31, 2012 (in thousands):

	June 30, 2013 (unaudited)							
		Gross	Gross					
	Amortized	Unrecognized	Unrecognized	Aggregate				
	Cost	Gains	Losses	Fair Value				
Current investments:								
Corporate debt securities	\$503	\$ —	\$ —	\$503				
Certificates of deposit	8,250	_		8,250				
Total current investments	\$8,753	\$ —	\$ —	\$8,753				
	Amortized Cost	Decembe Gross Unrecognized Gains	Gross Unrecognized Losses	Aggregate Fair Value				
C			200040	Tan value				
Current investments:		2 11222	2000	ran varue				
Current investments: Corporate debt securities	\$1,520	\$ —	\$ —	\$1,520				
	\$1,520 7,000							
Corporate debt securities	•			\$1,520				
Corporate debt securities Certificates of deposit	7,000	\$ <u> </u>	\$ <u> </u>	\$1,520 7,000				
Corporate debt securities Certificates of deposit	7,000	\$ <u> </u>	\$ <u> </u>	\$1,520 7,000				
Corporate debt securities Certificates of deposit Total current investments	7,000	\$ <u> </u>	\$ <u> </u>	\$1,520 7,000				

As of June 30, 2013, the current investments mature within one year.

Net (Loss) Income per Common Share

Basic (loss) income per share is computed using the weighted average number of common shares outstanding during the period, and excludes any dilutive effects of common stock equivalent shares, such as stock options, warrants, and convertible preferred stock. Diluted (loss) income per share is computed using the weighted average number of common shares outstanding and potentially dilutive common stock equivalent shares outstanding during the period. Common stock equivalent shares are excluded from the computation if their effect is anti-dilutive.

The Company's Series B Convertible Preferred stock ("Preferred Stock – Series B") is considered a participating security as the preferred stock participates in dividends with the common stock, which requires the use of the two-class method when computing basic and diluted earnings per share. The Preferred Stock – Series B is not required to absorb any net loss. Though the Company paid a one-time special dividend in 2012, the Company does not expect to continue to pay dividends on its common or preferred stock in the near future.

For the three and six months ended June 30, 2013, the Company has reported a net loss and as a result, basic and diluted net loss per common share are the same. Therefore, in calculating net loss per share amounts, shares underlying the potentially dilutive common stock equivalents were excluded from the calculation of diluted net income per common share because their effect was anti-dilutive.

Table of Contents

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except share and per share data) for the three and six months ended June 30, 2012:

	Thr	ee Months End	ded	Six Months Ended				
		June 30, 2012		•	June 30, 2012			
		(unaudited)			(unaudited)			
			Per Share			Per Share		
	Income	Shares	Amount	Income	Shares	Amount		
Basic EPS								
Net Income	\$577			\$125				
Income allocated to								
participating securities	140			30				
Income allocated to common								
shares	\$437	23,469,777	\$0.02	\$95	23,488,475	\$0.00		
Diluted EPS								
Diluted potential common								
shares (1)		1,697,828			1,856,304			
Income allocated to common								
shares	\$437	25,167,605	\$0.02	\$95	25,344,779	\$0.00		

⁽¹⁾ Dilutive potential common shares consist of shares of common stock issuable upon exercise of outstanding stock options and warrants.

The following is a table of the potentially dilutive common stock equivalents for the three and six month periods ended June 30, 2013 and 2012:

	Three months ended June						
	30),	Six months en	ded June 30,			
	2013	2012	2013	2012			
Options and warrants	5,605,713	3,005,164	5,605,713	2,704,361			
Convertible preferred stock	7,545,333		7,545,333				
Total potentially dilutive common stock equivalents	13,151,046	3,005,164	13,151,046	2,704,361			

Note 2: Accounts Receivable, net

The majority of the Company's commercial accounts receivable are due from Original Equipment Manufacturers ("OEM's"). Credit is extended based on an evaluation of a customer's financial condition and, generally, collateral is not required.

Accounts receivable consisted of the following (in thousands):

	Ju	June 30,		ecember
	2	2013		31,
	(una	audited)		2012
Accounts receivable	\$	5,095	\$	5,386
Less allowance for doubtful accounts		(232)		(232)
Net receivable	\$	4,863	\$	5,154

Table of Contents

Note 3: Inventories, net

The components of inventories are as follows (in thousands):

		June 30, 2013		ecember 31,
	(una	audited)		2012
Raw materials	\$	1,994	\$	1,745
Work in process		949		898
Finished goods		706		651
Total inventories		3,649		3,294
Less inventory reserve		(87)		(71)
Total inventories, net	\$	3,562	\$	3,223

Note 4: Line of Credit

At June 30, 2013, the Company had available a credit facility with Access Business Finance, LLC ("Access") under which the Company may borrow up to a maximum of \$3 million based on a borrowing base equivalent of 75% of eligible accounts receivable. The material terms of such credit facility are: the minimum monthly interest payment is \$1,000; the interest rate is Prime plus 5% but not less than 8.25%; and the early termination fee is \$6,000. The renewal date of the line of credit is September 1, 2013. The Company's obligations under the credit facility are secured by its assets. For the six months ended June 30, 2013, the Company had not borrowed on its line of credit.

Note 5: Stock-based Compensation

The Company uses the fair value method of accounting for share-based compensation arrangements. The fair value of stock options is estimated at the date of grant using the Black-Scholes option valuation model. Stock-based compensation expense is reduced for estimated forfeitures and is amortized over the vesting period using the straight-line method.

The following table summarizes the allocation of non-cash stock-based compensation to our expense categories for the three and six month periods ended June 30, 2013 and 2012 (in thousands):

	Three Months Ended				Six Months Ended			
	June 30,				June 30,			
	(unaudited)			(unaudited)			ed)	
		2013		2012		2013		2012
Cost of revenue	\$	72	\$	72	\$	151	\$	136
Research and development		137		146		292		287
Selling, general and administrative		250		433		635		977
Total stock compensation expense	\$	459	\$	651	\$	1,078	\$	1,400

At June 30, 2013, total unrecognized compensation costs related to stock options was approximately \$1.9 million, net of estimated forfeitures. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures and is expected to be recognized over a weighted average period of approximately 1.8 years.

Table of Contents

The following key assumptions were used in the Black-Scholes option pricing model to determine the fair value of stock options granted:

	For the Six Mo	onths Ended
	June 3	30,
	2013	2012
Dividend yield	0 %	0 %
		0.36 -
Risk free interest rates	0.35 - 1.48%	0.87 %
	70.9 to	71.8 to
Expected volatility	73.8%	81.2%
Expected term (in years)	3.5 to 5.0	3.0 to 5.5

The Company paid a special one-time dividend in 2012. However, the Company does not expect to continue to pay dividends in the near future therefore the Company used an expected dividend yield of 0%. The risk-free interest rate used in the Black-Scholes option pricing model is based on the implied yield currently available on U.S. Treasury securities with an equivalent term. Expected volatility is based on the weighted average historical volatility of the Company's common stock for the equivalent term. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on historical experience and vesting schedules of similar awards.

A summary of the Company's stock option activity for the six months ended June 30, 2013 is presented in the following table (unaudited):

			Weighted	
			Average	
		Weighted	Remaining	
		Average	Contractual	Aggregate
	Number of	Exercise	Life (In	Intrinsic
	Shares	Price	Years)	Value
Outstanding at December 31, 2012	4,685,434	\$3.82		
Options granted	236,411	3.50		
Options exercised	(163,615)	1.57		
Options forfeited	(64,949)	4.35		
Options cancelled or expired	(87,568)	6.61		
Outstanding at June 30, 2013	4,605,713	\$3.83	4.85	\$3,901,599
Vested or expected to vest at June 30, 2013 (1)	4,569,281	\$3.82	4.85	\$3,896,971
Exercisable at June 30, 2013	3,694,946	\$3.52	5.03	\$3,785,907

⁽¹⁾ The expected to vest options are the result of applying the pre-vesting forfeiture rate assumptions to total unvested options.

The aggregate intrinsic value in the table above represents the difference between the exercise price of the underlying options and the quoted price of the Company's common stock. For the three and six months ended June 30, 2013, the aggregate intrinsic value of options exercised was \$325 thousand and \$344 thousand, respectively. The Company issues new shares of common stock upon exercise of stock options.

Note 6: Shareholders' Equity

Preferred Stock - Series B Convertible Preferred Stock ("the Preferred Stock - Series B")

As of June 30, 2013 and December 31, 2012, there were 5,659 shares of Preferred Stock – Series B issued and outstanding.

Common Stock

The Company received approximately \$233 thousand and \$257 thousand for the exercise of 150,960 and 163,615 stock options in the three and six months ended June 30, 2013, respectively. The Company received approximately \$13 thousand and \$42 thousand for the exercise of 4,875 and 28,875 stock options in the three and six months ended June 30, 2012, respectively.

Table of Contents

Note 7: Income Taxes

The Company's effective tax rate is calculated quarterly based upon current assumptions relating to the full year's estimated operating results and various tax-related items. The Company's effective tax rate for the six months ended June 30, 2013 and 2012 was 0% and 37.2%, respectively. The difference between the effective tax rate of 0% and the U.S. federal statutory rate of 34% for the six months ended June 30, 2013 was primarily due to the impact of state income taxes and the change in the valuation allowance and the difference between the effective tax rate of 37.2% and the U.S. federal statutory rate of 34% for the six months ended June 30, 2012 was primarily due to the impact of state income taxes and alternative minimum tax.

Due to the Company's operating loss carryforwards, all tax years remain open to examination by the major taxing jurisdictions to which the Company is subject. In the event that the Company is assessed interest or penalties at some point in the future, it will be classified in the financial statements as tax expense.

The Company's deferred tax assets and their potential realizability are evaluated each quarter to determine if any changes should be made to the valuation allowance. As of June 30, 2013, the Company has determined based on the weight of the available evidence, both positive and negative, it is more likely than not that \$8.9 million of its deferred tax asset will be realized and no additional valuation allowance was released.

Note 8: Commitments and Contingencies

Royalty Payments

The Company signed a license agreement on March 29, 1999 with Eastman Kodak ("Kodak'), under which it is obligated to make royalty payments. Under this agreement, the Company must pay to Kodak a minimum royalty plus a certain percentage of net sales with respect to certain products, which percentages are defined in the agreement. The percentages are on a sliding scale depending on the amount of sales generated. Any minimum royalties paid will be credited against the amounts due based on the percentage of sales. The royalty agreement terminates upon the expiration of the issued patent which is the last to expire. The Company was notified that Kodak sold substantially all rights and obligations under the Company's license agreement to Global OLED Technology ("GOT") as of December 30, 2009.

In late 2008, the Company began evaluating the status of its manufacturing process and the use of the intellectual property ("IP") associated with its license agreement. After this analysis and after making a few changes to its manufacturing process, by the end of 2008 the Company had stopped using the IP covered under the license agreement. The last royalty payment under the license agreement was made in November 2009. The Company determined that it is no longer required to pay the minimum royalty payment and as such has not paid or accrued this amount.

In April 2011, the Company received a request for royalty payments from a representative of GOT. The Company responded stating that the licenses were no longer in force and that the request for royalties was untimely. Although GOT does not agree, both parties have expressed an interest in resolving the disagreement amicably. Communications to date have been preliminary regarding its resolution. The Company estimates that the range of loss contingency is between \$0 and \$250 thousand.

Operating Leases

The Company leases office facilities and office, lab and factory equipment under operating leases. Certain leases provide for payments of monthly operating expenses. The Company currently has lease commitments for space in

Hopewell Junction, New York, Bellevue, Washington, and Santa Clara, California.

The Company's manufacturing facilities are leased from IBM in Hopewell Junction, New York. The Company leases approximately 37,000 square feet to house its equipment for OLED microdisplay fabrication and for research and development, an assembly area and administrative offices. The lease expires May 31, 2014 with the option of extending the lease for five years. The corporate headquarters are located in Bellevue, Washington where eMagin leases approximately 6,300 square feet. The lease expires on August 31, 2014. In addition, the Company leases approximately 2,400 square feet of office space for design and product development in Santa Clara, California and the lease expires October 31, 2015.

Rent expense was approximately \$303 thousand and \$606 thousand, respectively, for the three and six months ended June 30, 2013 and approximately \$302 thousand and \$603 thousand, respectively, for the three and six months ended June 30, 2012.

Table of Contents

Equipment Purchase Commitments

The Company has committed to equipment purchases of \$0.4 million at June 30, 2013.

Note 9: Concentrations

For the three and six months ended June 30, 2013, approximately 66% and 64%, respectively, of the Company's net revenues were derived from customers in the United States and approximately 34% and 36%, respectively, of the Company's net revenues were derived from international customers. For the three and six months ended June 30, 2012, approximately 71% and 63%, respectively, of the Company's net revenues were derived from customers in the United States and approximately 29% and 37%, respectively, of the Company's net revenues were derived from international customers. For the three and six months ended June 30, 2013, two customers accounted for 33% and 26%, respectively, of its net revenue. For the three months ended June 30, 2012, two customers accounted for 33% of its revenue and for the six months ended June 30, 2012, one customer accounted for 16% of its revenue.

The following is a schedule of revenue by geographic location (in thousands):

	Three Months Ended June 30, (unaudited)			Six Months Ended June 30, (unaudited)		
	2013		2012	2013		2012
North and South America	\$ 4,718	\$	6,251	\$ 10,340	\$	9,611
Europe, Middle East, and Africa	1,905		1,713	4,012		3,770
Asia Pacific	405		623	1,179		1,343
Total	\$ 7,028	\$	8,587	\$ 15,531	\$	14,724

The Company purchases principally all of its silicon wafers from a single supplier located in Taiwan.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Statement of Forward-Looking Information

In this quarterly report, references to "eMagin Corporation," "eMagin," "Virtual Vision," "the Company," "we," "us," and "our" refer to eMagin Corporation and its wholly owned subsidiary, Virtual Vision, Inc.

Except for the historical information contained herein, some of the statements in this Report contain forward-looking statements that involve risks and uncertainties. These statements are found in the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operation" and "Risk Factors." They include statements concerning: our business strategy; expectations of market and customer response; liquidity and capital expenditures; future sources of revenues; expansion of our proposed product line; and trends in industry activity generally. In some cases, you can identify forward-looking statements by words such as "may," "will," "should," "expect," "plan," "could," "anticipate," "intend," "believe," "estimate," "predict," "potential," "goal," or "continue" or similar terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including, but not limited to, the risks outlined under "Risk Factors," that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. For example, assumptions that could cause actual results to vary materially from future results include, but are not limited to: our ability to successfully develop and market our products to customers; our ability to generate customer demand for our products in our target markets; the development of our target markets and market opportunities; our ability to manufacture suitable products at competitive cost; our ability to successfully launch new equipment on our manufacturing line; market pricing for our products and for competing products; the extent of increasing competition; technological developments in our target markets and the development of alternate, competing technologies in them; and sales of shares by existing shareholders. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Unless we are required to do so under federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements.

Overview

The second quarter saw eMagin reaffirm our technological leadership in the developing OLED microdisplay industry as we announced we have developed what we believe is the world's brightest color OLED microdisplay. The display delivers a high brightness of 1000 nits and is being commercialized as OLED-XLS. The OLED-XLS has received positive reviews from our customers and is currently being qualified for full production. We are investing in developing additional new technologies that provide even higher brightness displays as this is an important attribute for applications that are used in daylight or in direct sunlight such as aircraft cockpits and personal headsets. We also made further progress in bringing the color gamut of our new XGA display up towards meeting the levels requested by a camera manufacturer.

The second quarter financial results were driven primarily by the continued activity under the large defense related programs in our business portfolio. We continued shipping large numbers of Display Beam Combiner Assemblies (DBCAs), which is an assembly comprised of our SVGA display combined with an optic, to our customer Exelis for the Enhanced Night Vision Goggle II (ENVG II) program. Exelis Geospatial Systems was also awarded funding for production year 3 for ENVG II. We expect deliveries to continue into 2014. We continued our work designing and building a high brightness color 2,000 by 2,000 pixel display for NAVAIR (US Navy) targeted for avionic head mounted displays and high performance portable digital goggle systems. Additionally, we continued to ship displays for the FELIN Soldier Modernization Program in France, to FLIR in Sweden for three industrial thermal camera EVFs, to BCF Industries in Scotland for the BUG Binocular Ultra Sound Goggles, and for the completion of the

RED-I Thermal Weapon Site Remote Viewer program for the US Army.

eMagin's second quarter results reflect some of the challenges we face as an R&D provider, primarily for the U.S. government and as a leader in the developing worldwide OLED microdisplay market. Although product revenue (primarily displays) increased 15% year to date in 2013 over 2012, in the second quarter, overall revenues were lower than Q2 last year, due primarily to a \$1.2 million decrease in R&D contract revenue and a \$350,000 or 5% decrease in product revenue. However, for the first six months of 2013, total revenues increased 5.5% over last year. We have fewer R&D contracts this year, we believe due at least partially to the U.S. government sequester/budget issues. On the microdisplay side, displays shipped in Q2 for fiscal year 2013 decreased from Q2 last year due to manufacturing challenges including the time spent to improve yield on the new OLED deposition tool, and increased labor requirements of certain customers for newer generation displays. In Q2 for fiscal year 2013, most of the OLED deposition for our displays was accomplished using our new deposition tool. We are continuing to apply personnel and other resources to further optimize the tool to increase yield and output. Currently, the yields on both deposition tools are comparable. These efforts resulted in higher manufacturing costs in the quarter. Total gross margin of 34% was 19 points lower than O2 last year due to higher costs. Year-to-date, total gross margin for fiscal year 2013 is 9 points less than last year. Manufacturing costs increased due to increased manufacturing labor, the costs incurred in improving the performance of the new OLED deposition tool, increased depreciation due to new equipment, primarily the new OLED deposition tool and to the costs of concurrently running both OLED deposition tools this year as opposed to just the Satella deposition tool last year.

Table of Contents

Fiscal 2013 – Financial Outlook for the Year

For fiscal year 2013, we expect revenue growth over last year, driven by a significant increase in displays shipped, which will more than offset a decrease in R&D contract revenue. Our revenue expectation and our guidance for the year is total revenue in a range of \$32 million to \$35 million. eMagin's revenue last year in fiscal 2012 totaled \$30.6 million.

At June 30, 2013, we had a total of 103 full-time and part-time employees as compared to 100 employees at December 31, 2012.

A detailed discussion of our business may be found in Part I, "Business," of our 2012 Annual Report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission on March 14, 2013.

CRITICAL ACCOUNTING POLICIES

Revenue and Cost Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, selling price is fixed or determinable and collection is reasonably assured. Product revenue is generally recognized when products are shipped to customers. We defer revenue recognition on products sold directly to the consumer with a maximum thirty day right of return. Revenue is recognized upon the expiration of the right of return.

We also earn revenues from certain R&D activities (contract revenues) under both firm fixed-price contracts and cost-type contracts. Revenues relating to firm fixed-price contracts and cost-type contracts are generally recognized on the percentage-of-completion method of accounting as costs are incurred (cost-to-cost basis). Progress is generally based on a cost-to-cost approach however an alternative method may be used such as physical progress, labor hours or others depending on the type of contract. Physical progress is determined as a combination of input and output measures as deemed appropriate by the circumstances. Contract costs include all direct material and labor costs and an allocation of allowable indirect costs as defined by each contract, as periodically adjusted to reflect revised agreed upon rates. These rates are subject to audit by the other party.

Income Taxes

Our deferred tax assets and their potential realizability are evaluated each quarter to determine if any changes should be made to the valuation allowance. As of June 30, 2013, we have determined based on the weight of the available evidence, both positive and negative, it is more likely than not that \$8.9 million of our deferred tax asset will be realized and no additional valuation allowance was released.

Other critical accounting policies, as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, relate to product warranty, use of estimates, fair value of financial instruments and stock-based compensation, and additional information on accounting for income taxes.

RESULTS OF OPERATIONS

THREE AND SIX MONTHS ENDED JUNE 30, 2013 COMPARED TO THREE AND SIX MONTHS ENDED JUNE 30, 2012

Revenues

Revenues for the three and six months ended June 30, 2013 were approximately \$7.0 million and \$15.5 million, respectively, as compared to approximately \$8.6 million and \$14.7 million, respectively, for the three and six months ended June 30, 2012, a decrease of \$1.6 million for the three month period or 18% and an increase of approximately \$0.8 million or 5% for the six month period.

Product revenue is comprised primarily of sales of displays, as well as sales of Z800 systems, and other hardware. For the three months ended June 30, 2013, product revenue decreased approximately \$0.4 million or 5% as compared to the three months ended June 30, 2012. The decrease in revenue resulted primarily from shipping fewer displays than in Q2 of 2012. For the six months ended June 30, 2013, product revenue increased approximately \$1.9 million or 15% as compared to the six months ended June 30, 2012. The increase in revenue resulted from an increase in the number of DBCA units shipped and an increase in the number of displays shipped.

Contract revenue is comprised of revenue from research and development ("R&D") or non-recurring engineering ("NRE") contracts. For the three and six months ended June 30, 2013, contract revenue decreased approximately \$1.2 million and \$1.1 million, respectively, or 83% and 64%, respectively, as compared to the three and six months ended June 30, 2012. We had one active contract for the three and six months ended June 30, 2013 compared to five and six active contracts, respectively, for the three and six months ended June 30, 2012. We believe fewer R&D contracts are being awarded this year by the U.S. government agencies, the source of most of our R&D contracts historically. We believe this is due to the U.S. government sequester event and budget issues.

Cost of Goods Sold

Cost of goods sold is comprised of costs of product and contract revenues. Cost of product revenue includes materials, labor and manufacturing overhead related to our products. Cost of contract revenue includes direct and allocated indirect costs associated with performance of contracts. Cost of goods sold was approximately \$4.6 million and \$9.4 million, respectively, for the three and six month periods ended June 30, 2013 as compared to approximately \$4.1 million and \$7.5 million, respectively, for the three and six months ended June 30, 2012, an increase of approximately \$0.6 million and \$1.9 million, respectively, or 14% and 25%. Cost of goods sold as a percentage of revenues was 66% and 60%, respectively, for the three and six months ended June 30, 2013 as compared to 47% and 51%, respectively, for the three and six months ended June 30, 2012.

The following table outlines product, contract and total gross profit and related gross margins for the three months ended June 30, 2013 and 2012 (dollars in thousands):

	,	Three Months Ended June 30,				Six Months Ended June 30,			
		2013	2012		2013			2012	
		(unaudited)				(unau)		
Product revenue gross profit	\$	2,336	\$	3,644	\$	5,927	\$	6,172	
Product revenue gross margin		34% 51		51%	409			48%	
Contract revenue gross profit	\$	55	\$	869	\$	214	\$	1,022	
Contract revenue gross margin		21% 59%			34%		58%		
Total gross profit	\$	2,391	\$	4,513	\$	6,141	\$	7,194	
Total gross margin		34%)	53%		40%		49%	

The gross profit for the three and six months ended June 30, 2013 was approximately \$2.4 million and \$6.1 million, respectively, as compared to approximately \$4.5 million and \$7.2 million, respectively, for the three and six months ended June 30, 2012, a decrease of approximately \$2.1 million and \$1.1 million, respectively, or 47% and 15%, respectively, for the three and six month periods. Gross margin was 34% and 40%, respectively, for the three and six months ended June 30, 2013 as compared to 53% and 49%, respectively, for the three and six months ended June 30, 2012.

The product gross profit for the three and six months ended June 30, 2013 was approximately \$2.3 million and \$5.9 million, respectively, as compared to approximately \$3.6 million and \$6.2 million, respectively, for the three and six months ended June 30, 2012, a decrease of \$1.3 million and \$0.3 million, respectively, for the three and six month periods. Product gross margin was 34% and 40%, respectively, for the three and six months ended June 30, 2013 down from 51% and 48%, respectively, for the three and six month periods ended June 30, 2012. The lower gross margin for Q2 2013 is due to higher costs, primarily labor costs required for production and for the effort to increase the yield and output of the new OLED deposition tool. We are incurring increased material costs due to lower yield and also due to concurrently running both deposition tools this year compared to only the Satella deposition tool in the first six months of 2012. Depreciation expense has increased due to new equipment coming online, including the new

deposition tool.

The contract gross profit was approximately \$0.06 million and \$0.2 million, respectively, for the three and six months ended June 30, 2013 as compared to \$0.9 million and \$1.0 million, respectively, for the three and six months ended June 30, 2012. For the three and six months ended June 30, 2013, contract gross margin decreased to 21% and 34%, respectively, down from 59% and 58%, respectively, for the three and six months ended June 30, 2012. The change in the contract gross margin is due to the nature of the contract and the amount of third party expenses incurred in fulfilling the contract.

Table of Contents

Operating Expenses

Research and Development. Research and development expenses are company-funded and include salaries and related benefits, development materials and other costs specifically allocated to the development of new technologies and microdisplay products, OLED materials and subsystems. R&D related costs associated with fulfilling contracts are categorized as contract cost of goods sold. R&D expenses for the three and six months ended June 30, 2013 were approximately \$1.5 million and \$2.6 million, respectively, or 21% and 17%, respectively, of revenue as compared to approximately \$1.3 million and \$2.4 million, respectively, or 15% and 16%, respectively, of revenue for the three and six months ended June 30, 2012. The increase was due primarily to an increase in internal research and development costs.

Selling, General and Administrative. Selling, general and administrative ("SG&A") expenses consist principally of salaries and related benefits, professional services fees and marketing, general corporate, and administrative expenses. Selling, general and administrative expenses for the three and six months ended June 30, 2013 were approximately \$2.1 million and \$4.3 million, respectively, or 30% and 28%, respectively, of revenue as compared to approximately \$2.3 million and \$4.6 million, respectively, or 27% and 31%, respectively, of revenue for the three and six months ended June 30, 2012. The decrease in SG&A expenses was due primarily to a decrease in stock compensation, consulting and incentive compensation expenses.

Other Income (Expense), net. Other income (expense), net consists primarily of interest income earned on investments, interest expense and gain on sale of assets. For the three and six months ended June 30, 2013, interest expense was approximately \$11 thousand and \$21 thousand, respectively, as compared to approximately \$5 thousand and \$8 thousand, respectively, offset by the capitalization of interest of \$5 thousand and \$13 thousand, respectively, for the three and six months ended June 30, 2012. We have no debt upon which we are incurring interest expense however we pay fees to keep our line of credit available. Other income for the three and six months ended June 30, 2013 was approximately \$13 thousand and \$24 thousand, respectively, of interest income and \$9 thousand from gain on sale of assets as compared to approximately \$12 thousand and \$18 thousand, respectively, of interest income for the three and six months ended June 30, 2012.

Liquidity and Capital Resources

We had approximately \$13.4 million of cash, cash equivalents, and investments at June 30, 2013 and December 31, 2012. Of the \$13.4 million in cash, approximately \$8.8 million was invested in certificates of deposits ("CDs") and corporate bonds.

Cash flow provided by operating activities during the six months ended June 30, 2013 was approximately \$0.3 million, attributable to our net non-cash expenses of \$1.5 million offset by our net loss of approximately \$0.8 million and change in operating assets and liabilities of \$0.4 million. Cash flow provided by operating activities during the six months ended June 30, 2012 was approximately \$0.4 million, attributable to our net income of approximately \$0.1 million and net non-cash expenses of \$1.5 million offset by the change in operating assets and liabilities of \$1.2 million.

Cash used in investing activities during the six months ended June 30, 2013 was approximately \$0.3 million of which \$0.6 million was used to purchase equipment offset by net proceeds of \$0.3 million of short-term investments. Presently we have committed approximately \$0.4 million for capital expenditures for the balance of 2013. Cash used in investing activities during the six months ended June 30, 2012 was approximately \$3.6 million of which \$2.6 million purchased investments in CDs and corporate bonds and approximately \$1.0 million purchased equipment primarily for upgrading our production line.

Cash provided by financing activities during the six months ended June 30, 2013 was proceeds from the exercise of stock options of approximately \$0.3 million as compared to cash used by financing activities during the six months ended June 30, 2012 was approximately \$0.3 million, primarily representing the purchase of treasury stock.

Credit Facility

At June 30, 2013, we had a credit facility with Access Business Finance, LLC ("Access") that provides for up to a maximum amount of \$3 million based on a borrowing base equivalent of 75% of eligible accounts receivable. The interest on the credit facility is equal to the Prime Rate plus 5% but may not be less than 8.25% with a minimum monthly interest payment of \$1 thousand. The credit facility will automatically renew on September 1, 2013 for a one year term unless written notice is provided. We did not draw on our credit facility during the six months ended June 30, 2013 or at any time since its inception in September 2010 and there is no outstanding balance.

The credit facility contains the customary representations and warranties as well as affirmative and negative covenants. We were in compliance with all debt covenants as of June 30, 2013.

Table of Contents

We expect our business to experience revenue growth which may result in higher accounts receivable levels and may require increased production and/or higher inventory levels. We anticipate that our cash needs to fund these requirements as well as other operating or investing cash requirements over the next twelve months will be less than our current cash on hand, investments and the cash we anticipate generating from operations. We anticipate that we will not require additional funds over the next twelve months other than perhaps for discretionary capital spending. If unanticipated events arise during the next twelve months, we believe we can raise sufficient funds. However, if we are unable to obtain sufficient funds, we may have to reduce the size of our organization and/or be forced to reduce and/or curtail our production and operations, all of which could have a material adverse impact on our business prospects.

Off-Balance Sheet Arrangements

We do not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, results of operations, liquidity or capital expenditures.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Market rate risk

We are exposed to market risk related to changes in interest rates.

Interest rate risk

We hold our cash in cash and cash equivalents, certificates of deposits, and corporate bonds. We do not hold derivative financial instruments or equity securities. At June 30, 2013, we have not drawn on our revolving line of credit and therefore do not have any related interest rate risk. A change in interest rates would not have had a material effect on our consolidated financial position, results of operations, or cash flows in the three and six months ended June 30, 2013.

Foreign currency exchange rate risk

We do not have any material foreign currency exchange rate risk.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective.

Limitations on the Effectiveness of Internal Controls.

Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

Changes in Internal Controls.

There were no changes in our internal controls over financial reporting during the fiscal quarter ended June 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. Legal Proceedings

None.

ITEM 1A. Risk Factors

In addition to other information set forth in this Report, you should carefully consider the risk factors previously disclosed in "Item 1A to Part 1" of our Annual Report on Form 10-K for the year ended December 31, 2012. There were no material changes from the risk factors during the six months ended June 30, 2013.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Issuer Repurchases of Equity Securities

None.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

None.

ITEM 5. Other Information

None.

ITEM 6. Exhibits

<u>31.1</u>	Certification by Chief Executive Officer pursuant to Sarbanes Oxley Section 302 (1)
<u>31.2</u>	Certification by Chief Financial Officer pursuant to Sarbanes Oxley Section 302 (1)
32.1	Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350 (1)
<u>52.1</u>	Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1550 (1)
<u>32.2</u>	Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (1)
101.INS	XBRL Instance Document (2)
101.SCH	XBRL Taxonomy Extension Schema Document (2)

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document (2)
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document (2)
101.LAB	XBRL Taxonomy Extension Label Linkbase Document (2)
	•
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document (2)

(1) Filed herewith.

(2) Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 6th day of August 2013.

eMAGIN CORPORATION

By: /s/ Andrew G. Sculley

Andrew G. Sculley Chief Executive Officer Principal Executive Officer

By: /s/ Paul Campbell

Paul Campbell

Chief Financial Officer

Principal Accounting and Financial

Officer